Study shows docetaxel combined with gemcitabine is active in metastatic breast cancer

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY-NEW YORK | 2001年 / 15卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1517 / 1517
页数：1
相关论文
共 50 条
  • [41] Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study
    G. P. Stathopoulos
    D. Tsavdaridis
    N. A. Malamos
    S. K. Rigatos
    Ch. Kosmas
    N. Pergantas
    J. G. Stathopoulos
    J. Xynotroulas
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 487 - 491
  • [42] Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer -: A phase II study
    Hausmaninger, H
    Morack, G
    Heinrich, B
    Wallwiener, D
    Höffken, K
    Buksmaui, S
    Krejcy, K
    Miller, MA
    Possinger, K
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (04): : 429 - 435
  • [43] Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
    Yi Li
    Yannan Zhao
    Chengcheng Gong
    Yizhao Xie
    Xichun Hu
    Jian Zhang
    Leiping Wang
    Sheng Zhang
    Jun Cao
    Zhonghua Tao
    Biyun Wang
    Scientific Reports, 9
  • [44] Phase III study of gemcitabine plus docetaxel versus capecitabine plus docetaxel for anthracycline-pretreated metastatic breast cancer patients: survival results
    Chan, S.
    Romieu, G.
    Huober, J.
    Tubiana-Hulin, M.
    Schneeweiss, A.
    Lluch, A.
    Llombart, A.
    du Bois, A.
    Carrasco, E.
    Thareau, Vaury A.
    Fumoleau, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S68 - S68
  • [45] Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
    Li, Yi
    Zhao, Yannan
    Gong, Chengcheng
    Xie, Yizhao
    Hu, Xichun
    Zhang, Jian
    Wang, Leiping
    Zhang, Sheng
    Cao, Jun
    Tao, Zhonghua
    Wang, Biyun
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [46] Single-agent gemcitabine is active in previously treated metastatic breast cancer
    Spielmann, M
    Llombart-Cussac, A
    Kalla, S
    Espié, M
    Namer, M
    Ferrero, JM
    Diéras, V
    Fumoleau, P
    Cuvier, C
    Perrocheau, G
    Ponzio, A
    Kayitalire, L
    Pouillart, P
    ONCOLOGY, 2001, 60 (04) : 303 - 307
  • [47] Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first line treatment of metastatic breast cancer: Results of a multicenter phase II study
    Riccardi, A
    Brugnatelli, S
    Danova, M
    Giordano, M
    Pugliese, P
    Luchena, G
    Grasso, D
    Trotti, G
    Berte, R
    Pansini, G
    Tinelli, C
    TUMORI, 2006, 92 (01) : 6 - 12
  • [48] A COMPARISON OF FIRST-LINE TREATMENT WITH GEMCITABINE PLUS DOCETAXEL VERSUS GEMCITABINE PLUS VINORELBINE IN WOMEN WITH METASTATIC BREAST CANCER
    Bensalem, A.
    Bouzid, K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [49] Safety and efficacy of first-line docetaxel (DXL) - gemcitabine (GMZ) in metastatic breast cancer (MBC)
    Bensalem, A.
    Bouzid, K.
    EJC SUPPLEMENTS, 2005, 3 (02): : 131 - 131
  • [50] In vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer: General concepts and future perspectives
    Alexopoulos, A
    Karamouzis, MV
    Rigatos, G
    SEMINARS IN ONCOLOGY, 2004, 31 (02) : 25 - 30
12345